Stem definition | Drug id | CAS RN |
---|---|---|
4410 | 110078-46-1 |
Dose | Unit | Route |
---|---|---|
16.80 | mg | P |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 10 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 70 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.77 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Date | Agency | Company | Orphan |
---|---|---|---|
Dec. 15, 2008 | FDA | GENZYME |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Venoocclusive liver disease | 65.03 | 32.61 | 15 | 855 | 4246 | 50600008 |
Febrile neutropenia | 41.80 | 32.61 | 24 | 846 | 97643 | 50506611 |
Thrombocytopenia | 35.88 | 32.61 | 24 | 846 | 127649 | 50476605 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Brain teratoma | 59.51 | 30.50 | 7 | 733 | 14 | 29573773 |
Febrile neutropenia | 37.32 | 30.50 | 27 | 713 | 112213 | 29461574 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Febrile neutropenia | 108.18 | 33.60 | 60 | 1302 | 187597 | 64309773 |
Mucosal inflammation | 81.42 | 33.60 | 35 | 1327 | 62549 | 64434821 |
Venoocclusive liver disease | 62.32 | 33.60 | 18 | 1344 | 9997 | 64487373 |
Thrombocytopenia | 57.22 | 33.60 | 43 | 1319 | 223758 | 64273612 |
Ascites | 44.40 | 33.60 | 23 | 1339 | 61978 | 64435392 |
Blood stem cell harvest failure | 41.85 | 33.60 | 6 | 1356 | 92 | 64497278 |
Herpes simplex | 40.17 | 33.60 | 13 | 1349 | 10523 | 64486847 |
Escherichia infection | 39.28 | 33.60 | 14 | 1348 | 15154 | 64482216 |
None
Source | Code | Description |
---|---|---|
ATC | L03AX16 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSTIMULANTS IMMUNOSTIMULANTS Other immunostimulants |
MeSH PA | D019380 | Anti-HIV Agents |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D044966 | Anti-Retroviral Agents |
MeSH PA | D000998 | Antiviral Agents |
FDA PE | N0000178324 | Increased Hematopoietic Stem Cell Mobilization |
FDA EPC | N0000178326 | Hematopoietic Stem Cell Mobilizer |
CHEBI has role | CHEBI:35610 | antineoplastic agents |
CHEBI has role | CHEBI:50847 | Immunologic adjuvant |
CHEBI has role | CHEBI:64946 | anti-AIDS agent |
CHEBI has role | CHEBI:145438 | CXCR4 antagonists |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Multiple myeloma | indication | 109989006 | DOID:9538 |
Peripheral Mobilization of Hematopoietic Stem Cells | indication | ||
Nontraumatic splenic rupture | contraindication | 43325004 | |
Leukemia, disease | contraindication | 93143009 | DOID:1240 |
Leukocytosis | contraindication | 111583006 | |
Impaired renal function disorder | contraindication | 197663003 | |
Pregnancy, function | contraindication | 289908002 | |
Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
Breastfeeding (mother) | contraindication | 413712001 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 11.45 | Basic |
pKa2 | 10.85 | Basic |
pKa3 | 8.05 | Basic |
pKa4 | 7.33 | Basic |
pKa5 | 7.16 | Basic |
pKa6 | 6.94 | Basic |
pKa7 | 3.22 | Basic |
pKa8 | 2.61 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
24MG/1.2ML (20MG/ML) | MOZOBIL | GENZYME | N022311 | Dec. 15, 2008 | RX | SOLUTION | SUBCUTANEOUS | 6987102 | July 22, 2023 | USE IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELLS TO PERIPHERAL BLOOD FOR COLLECTION & SUBSEQUENT AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH NON-HODGKINS LYMPHOMA & MULTIPLE MYELOMA |
24MG/1.2ML (20MG/ML) | MOZOBIL | GENZYME | N022311 | Dec. 15, 2008 | RX | SOLUTION | SUBCUTANEOUS | 7897590 | July 22, 2023 | USE IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELLS TO PERIPHERAL BLOOD FOR COLLECTION & SUBSEQUENT AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH NON-HODGKINS LYMPHOMA & MULTIPLE MYELOMA |
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
C-X-C chemokine receptor type 4 | GPCR | PARTIAL AGONIST | Ki | 6.05 | CHEMBL | CHEMBL | |||
C-C chemokine receptor type 2 | GPCR | IC50 | 10.40 | CHEMBL | |||||
Stromal cell-derived factor 1 | Cytokine | WOMBAT-PK | |||||||
C-C chemokine receptor type 4 | GPCR | ANTAGONIST | IC50 | 6.19 | IUPHAR | ||||
Atypical chemokine receptor 3 | GPCR | AGONIST | EC50 | 6.85 | IUPHAR | ||||
C-X-C chemokine receptor type 4 | GPCR | IC50 | 6.97 | CHEMBL |
ID | Source |
---|---|
D08971 | KEGG_DRUG |
4028232 | VUID |
N0000177944 | NUI |
4028232 | VANDF |
C1955474 | UMLSCUI |
CHEBI:125354 | CHEBI |
CHEMBL18442 | ChEMBL_ID |
CHEMBL2311028 | ChEMBL_ID |
DB06809 | DRUGBANK_ID |
C088327 | MESH_SUPPLEMENTAL_RECORD_UI |
844 | IUPHAR_LIGAND_ID |
8513 | INN_ID |
S915P5499N | UNII |
65015 | PUBCHEM_CID |
733003 | RXNORM |
159539 | MMSL |
26078 | MMSL |
d07372 | MMSL |
012924 | NDDF |
442206008 | SNOMEDCT_US |
442264009 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Mozobil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0024-5862 | INJECTION, SOLUTION | 24 mg | SUBCUTANEOUS | NDA | 26 sections |